XWEL
XWELL, Inc.0.7400
-0.0100-1.33%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
4.27MP/E (TTM)
-Basic EPS (TTM)
-3.34Dividend Yield
0%Recent Filings
8-K
XWELL closes $31M placement
XWELL closed a $31.3M private placement of Series H Preferred Stock and warrants on February 27 and March 3, 2026, issuing 31,333 preferred shares convertible into 66.7M common shares at $0.47 and warrants for another 66.7M at $0.345. Proceeds funded a $9M repurchase of Series G preferred, notes, and warrants, eliminating the series via filing on March 4. Cleaned balance sheet. Placement agent got warrants for 5.3M shares.
8-K
XWELL raises $31.3M, clears debt
XWELL inked a $31.3M private placement of Series H preferred stock and warrants on February 24, 2026, closing February 26. Proceeds fund a $9M repurchase of all outstanding Series G preferred, notes, and warrants from prior investors, clearing legacy obligations. Directors locked up shares for three months.
8-K
Stockholders approve key proposals
XWELL stockholders reelected five directors on December 18, 2025, ratified CBIZ CPAs as auditors, and approved executive pay every three years, a reverse stock split up to 1-for-20, and share issuances for Series G Preferred, warrants, and notes. Board declassification failed. Continuity holds, dilution risk rises.
8-K
Nasdaq bid price deficiency
XWELL received a Nasdaq delisting warning on December 1, 2025, after its stock's closing bid price stayed below $1.00 for 30 straight business days from October 17 to November 28. It has 180 days until June 1, 2026, to sustain $1.00 closes for 10 consecutive days. Trading continues uninterrupted. No assurance of compliance.
10-Q
Q3 FY2025 results
XWELL's Q3 revenue dipped 13% y/y to $7.3M, driven by lower XpresTest CDC funding, yet operating loss narrowed sharply to $0.8M from $4.8M as G&A plunged 76% on cost cuts and $2.3M employee retention credit. Gross profit held at $1.5M (20.3% margin), with XpresTest contributing $2.5M operating income while XpresSpa and Naples Wax posted modest losses. Cash burned $8.7M in operating activities YTD (derived), ending at $4.0M plus $0.2M marketable securities; Series G Preferred issued Jan 2025 for $4M (cash, redeemable quarterly at 107% premium). Warrants reclassified to equity May 2025. Ongoing Atlanta airport arbitration looms into 2026.
APDN
Applied DNA Sciences, Inc.
5.62+1.35
BDSX
Biodesix, Inc.
7.90+0.38
BIAF
bioAffinity Technologies, Inc.
1.38-0.10
CODX
Co-Diagnostics, Inc.
0.25-0.02
DGX
Quest Diagnostics Incorporated
178.66-5.45
IDXG
Interpace Biosciences, Inc.
1.14-0.02
LH
Labcorp Holdings Inc.
258.11-5.22
MDXH
MDxHealth SA
3.36+0.05
PSNL
Personalis, Inc.
7.98-0.50
VRAX
Virax Biolabs Group Limited
0.40-0.01